Imigran Nasal spray 6 doses

Imigran is the original branded sumatriptan, the first triptan developed for acute migraine treatment. It is available as tablets, nasal spray, and subcutaneous injection. The injection provides the fastest onset (within 10 minutes) and is used for severe attacks or when vomiting prevents oral or nasal administration. Sumatriptan constricts dilated cranial blood vessels and inhibits inflammatory neuropeptide release.

How to Take Imigran

Take Imigran (sumatriptan) as soon as the migraine headache begins. It is not intended for prevention and does not work if taken before the headache phase starts. Tablets should be swallowed whole with water. For the nasal spray, administer one spray into one nostril. For the injection, inject subcutaneously into the outer thigh or upper arm.

If the migraine returns after initial relief, a second dose may be taken at least two hours after the first. Do not take more than two doses in 24 hours. If the first dose provides no relief at all during the same attack, a second dose is unlikely to help and should not be taken for that attack.

Tablets: 50 to 100 mg per dose, maximum 300 mg daily. Nasal spray: 10 to 20 mg, maximum 40 mg daily. Injection: 6 mg subcutaneously, maximum 12 mg daily.

Common Side Effects

Common side effects include:

• Tingling, warmth, or flushing
• Chest tightness or pressure (usually brief and benign, but see below)
• Heaviness or pressure in the limbs
• Drowsiness
• Nausea
• Injection site reactions (with the injection form)

Chest tightness is reported by some people taking Imigran and is usually a transient, non-cardiac effect. However, if chest pain is severe, lasts more than a few minutes, or radiates to the arm or jaw, seek emergency medical care immediately, as triptans should not be used in patients with heart disease.

Not for hemiplegic or basilar migraine. Do not use within 24 hours of another triptan or ergotamine. Cardiovascular assessment recommended before first use in patients with risk factors.

Contraindicated in ischaemic heart disease, uncontrolled hypertension, previous stroke or TIA, severe hepatic impairment, and concurrent MAO inhibitor use.